Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma lipoprotein changes in humans induced by beta-interferon.

I B Rosenzweig1, D A Wiebe, E C Borden

  • 1Department of Pathology, University of Wisconsin, Madison 53792.

Atherosclerosis
|October 1, 1987
PubMed
Summary

Recombinant interferon-beta serine (IFN-beta ser) impacts patient lipoprotein lipids dose-dependently. This therapy reduced LDL cholesterol but increased triglycerides, with effects varying by dosage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The prevalence of anxiety disorders in dermatology outpatients: A systematic review and meta-analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023
Same author

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Recipient and donor age impact the risk of developing chronic GvHD in children after allogeneic hematopoietic transplant.

Bone marrow transplantation·2016
Same author

Comorbidity burden in patients with chronic GVHD.

Bone marrow transplantation·2013
Same author

Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center.

Bone marrow transplantation·2012
Same author

A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth.

Oncogene·2012

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Background:

  • Interferon-beta serine (IFN-beta ser) is a therapeutic agent with known biological effects.
  • Understanding its impact on lipid metabolism is crucial for patient management and therapeutic optimization.

Purpose of the Study:

  • To investigate the dose-dependent effects of recombinant DNA-derived interferon-beta serine (IFN-beta ser) on lipoprotein lipids in patients.
  • To determine the time course and magnitude of changes in cholesterol and triglyceride levels following IFN-beta ser administration.

Main Methods:

  • Two groups of patients received either 4.5 X 10(6) U or 90 X 10(6) U of IFN-beta ser intravenously daily for 10 days.
  • Plasma lipid profiles, including total cholesterol, LDL cholesterol, and triglyceride concentrations, were monitored throughout the study period.

Related Experiment Videos

Main Results:

  • IFN-beta ser administration resulted in a dose-dependent decrease in plasma total cholesterol and LDL cholesterol levels.
  • Low-dose and high-dose IFN-beta ser led to 9% and 23% reductions in total cholesterol, and 28% and 50% reductions in LDL cholesterol, respectively.
  • A dose-related increase in plasma triglyceride concentrations was observed, with a 74% increase in the low-dose group and a 136% increase in the high-dose group after 9 days.
  • HDL-cholesterol levels remained largely unaffected by IFN-beta ser treatment.
  • Cholesterol reduction and triglyceride increases exhibited different time courses, suggesting distinct underlying mechanisms.

Conclusions:

  • Recombinant interferon-beta serine significantly alters lipoprotein lipid profiles in a dose-dependent manner.
  • The observed effects on cholesterol and triglycerides suggest complex interactions within lipid metabolism pathways influenced by IFN-beta ser.
  • Further research is warranted to elucidate the mechanisms driving these lipid changes and their clinical implications.